These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31611263)

  • 21. Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study.
    Madhusoodanan S; Brenner R; Moise D; Sindagi J; Brafman I
    Ann Clin Psychiatry; 1998 Sep; 10(3):117-20. PubMed ID: 9781475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study.
    Primavera D; Manchia M; Deriu L; Tusconi M; Collu R; Scherma M; Fadda P; Fratta W; Carpiniello B
    BMJ Open; 2017 May; 7(5):e014938. PubMed ID: 28550022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease.
    Tedroff J; Waters S; Barker RA; Roos R; Squitieri F;
    J Huntingtons Dis; 2015; 4(2):131-40. PubMed ID: 26397894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease.
    Alpay M; Koroshetz WJ
    Psychosomatics; 2006; 47(1):70-2. PubMed ID: 16384811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical motor manifestations of Huntington disease.
    McGarry A; Biglan KM
    Handb Clin Neurol; 2017; 144():93-98. PubMed ID: 28947128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 27. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.
    Johnston TG
    Int Clin Psychopharmacol; 2011 Mar; 26(2):114-9. PubMed ID: 21119522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders.
    Anderson KE; van Duijn E; Craufurd D; Drazinic C; Edmondson M; Goodman N; van Kammen D; Loy C; Priller J; Goodman LV
    J Huntingtons Dis; 2018; 7(3):355-366. PubMed ID: 30040737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Huntington's disease: clinical presentation and treatment.
    Novak MJ; Tabrizi SJ
    Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evidence-based approach in the treatment of Huntington's disease.
    Mestre TA; Ferreira JJ
    Parkinsonism Relat Disord; 2012 May; 18(4):316-20. PubMed ID: 22177624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical management of motor manifestations of Huntington disease.
    McCusker EA; Loy CT
    Handb Clin Neurol; 2017; 144():141-150. PubMed ID: 28947112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.
    Loi SM; Walterfang M; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):376-380. PubMed ID: 29687724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating psychosis in movement disorder patients: a review.
    Borek LL; Friedman JH
    Expert Opin Pharmacother; 2014 Aug; 15(11):1553-64. PubMed ID: 24846479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and psychiatric characterization of patients with Huntington's disease and their at-risk relatives.
    Soliveri P; Monza D; Piacentini S; Paridi D; Nespolo C; Gellera C; Mariotti C; Albanese A; Girotti F
    Neurol Sci; 2002 Sep; 23 Suppl 2():S105-6. PubMed ID: 12548365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of psychosis in movement disorder patients.
    Chou KL; Borek LL; Friedman JH
    Expert Opin Pharmacother; 2007 May; 8(7):935-43. PubMed ID: 17472539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Not Available].
    Van Der Weijde E; Schadé A
    Tijdschr Psychiatr; 2015; 57(8):625. PubMed ID: 26437479
    [No Abstract]   [Full Text] [Related]  

  • 37. A Genetic Study of Psychosis in Huntington's Disease: Evidence for the Involvement of Glutamate Signaling Pathways.
    Tsuang DW; Greenwood TA; Jayadev S; Davis M; Shutes-David A; Bird TD
    J Huntingtons Dis; 2018; 7(1):51-59. PubMed ID: 29480208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?
    Killoran A; Biglan KM
    Mov Disord; 2014 Sep; 29(11):1404-13. PubMed ID: 25164707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurocognitive growth charting in psychosis spectrum youths.
    Gur RC; Calkins ME; Satterthwaite TD; Ruparel K; Bilker WB; Moore TM; Savitt AP; Hakonarson H; Gur RE
    JAMA Psychiatry; 2014 Apr; 71(4):366-74. PubMed ID: 24499990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.